

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 March 2023 (02.03.2023)



(10) International Publication Number
WO 2023/025932 A1

(51) International Patent Classification:

C07K 16/24 (2006.01) A61K 39/00 (2006.01)

(21) International Application Number:

PCT/EP2022/073766

(22) International Filing Date:

26 August 2022 (26.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/237,630 27 August 2021 (27.08.2021) US
63/364,734 16 May 2022 (16.05.2022) US

(71) Applicant: **MEDIMMUNE LIMITED** [GB/GB]; Mil-stein Building, Granta Park, Cambridge CB21 6GH (GB).

(72) Inventors: **SADIQ, Muhammad Waqas**; AstraZeneca AB, SE-151 85 Södertälje (SE). **LOZANO, Eulalia Jimenez**; AstraZeneca Farmacéutica Spain, S.A., Parque Norte, Edificio Álamo, C/ Serrano Galvache, 28033 Madrid (ES).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(54) Title: TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH AN ANTI-INTERLEUKIN-33 ANTI-BODY

(57) Abstract: The present disclosure relates to methods of treating COPD, particularly by administering an anti-IL-33 antibody or antibody variant thereof in a specified dosing regimen.



WO 2023/025932 A1